Targeted Drugs With Companion Dx May Draw Medicare NCD Interest – Phurrough
Executive Summary
Targeted drugs indicated for use with companion diagnostics raise the kind of reimbursement concerns that may make them eligible topics for a Medicare national coverage determination, Steve Phurrough, former director of the Centers for Medicare and Medicaid Services coverage and analysis group, suggests.
You may also be interested in...
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012
Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.
CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease
The Centers for Medicare and Medicaid Services has decided not to proceed with a national coverage determination for erythropoiesis-stimulating agents in patients with chronic kidney disease, according to a proposed decision memo released March 16.